• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cybin Inc. - Common Stock (NQ:HELP)

    5.425 +0.025 (+0.46%)
    Streaming Delayed Price Updated: 10:10 AM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 326,315
    Open 5.380
    Bid (Size) 5.410 (300)
    Ask (Size) 5.440 (300)
    Prev. Close 5.400
    Today's Range 5.210 - 5.500
    52wk Range 4.290 - 8.970
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
    Via Investor Brand Network
    News headline image
    Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
    From Helus Pharma
    Via GlobeNewswire

    Performance

    YTD
    -29.8%
    -29.8%
    1 Month
    +25.6%
    +25.6%
    3 Month
    -26.0%
    -26.0%
    6 Month
    -29.8%
    -29.8%
    1 Year
    -29.8%
    -29.8%

    More News

    Read More
    BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board
    Via Investor Brand Network
    News headline image
    Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
    From Helus Pharma
    Via GlobeNewswire
    PsychedelicNewsBreaks –  Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
    Via Investor Brand Network
    InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office
    Via Investor Brand Network
    News headline image
    Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
    From Helus Pharma
    Via GlobeNewswire
    TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Ken Kramer SVP Medical Affairs
    Via Investor Brand Network
    News headline image
    Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
    From Helus Pharma
    Via GlobeNewswire
    PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer
    Via Investor Brand Network
    News headline image
    Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside ↗
    Via Stocktwits
    News headline image
    Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours ↗
    Via Stocktwits
    Topics ETFs Stocks
    BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
    Via Investor Brand Network
    News headline image
    Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
    Via FinancialNewsMedia
    News headline image
    HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗
    Via Stocktwits
    News headline image
    Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
    From Helus Pharma
    Via GlobeNewswire
    TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
    Via Investor Brand Network
    News headline image
    Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
    Via FinancialNewsMedia
    News headline image
    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
    Via FinancialNewsMedia
    News headline image
    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
    Via MarketBeat
    News headline image
    HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ ↗
    Via Stocktwits
    PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
    Via Investor Brand Network

    Frequently Asked Questions

    Is Cybin Inc. - Common Stock publicly traded?
    Yes, Cybin Inc. - Common Stock is publicly traded.
    What exchange does Cybin Inc. - Common Stock trade on?
    Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cybin Inc. - Common Stock?
    The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
    What is the current price of Cybin Inc. - Common Stock?
    The current price of Cybin Inc. - Common Stock is 5.425
    When was Cybin Inc. - Common Stock last traded?
    The last trade of Cybin Inc. - Common Stock was at 04/28/26 10:10 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.